This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slivka, A. Articles by Levy, D. Search for Related Content PubMed PubMed Citation Articles by Slivka, A. Articles by Levy, D.

Stroke, Vol 21, 1657-1662, Copyright © 1990 by American Heart Association

ARTICLES

Natural history of progressive ischemic stroke in a population treated with heparin

A Slivka and D Levy
Department of Neurology, New York Hospital-Cornell Medical Center, New York.

Data on the acute natural history of progressive stroke with or without heparin treatment are limited. To define the acute course of patients treated with heparin for progressive stroke, we examined the charts of 69 such patients identified through the Cornell Neurology Database from October 1979 to June 1985. Analysis included determining whether further clinical deterioration or hemorrhagic complications were associated with readily identifiable clinical or laboratory variables. Twenty-five patients (36%) continued to deteriorate while receiving heparin, another two (3%) worsened due to intracerebral hemorrhage, and a total of 10 patients (14%) had bleeding complications. No clinical features or heparin dosing regimens distinguished the patients likely to benefit from heparin. Clinical progression or hemorrhage did not correlate with the level of anticoagulation as measured by the average heparin dose per day or the mean partial thromboplastin time. Without unequivocal evidence demonstrating heparin's ineffectiveness for progressive stroke, many clinicians managing such patients will continue to use heparin. Our results suggest that this decision should not be governed by such clinical features as a patient's age or sex or by the vascular distribution of the stroke. Furthermore, frequent measurement of and overzealous efforts to adjust the partial thromboplastin time may be unnecessary since it does not correlate with outcome.

This article has been cited by other articles:

				G. J. del Zoppo TIAs and the pathology of cerebral ischemia Neurology, April 27, 2004; 62(8_suppl_6): S15 - S19. [Full Text]

				T. F. Choudhri, B. L. Hoh, C. J. Prestigiacomo, J. Huang, L. J. Kim, A. M. Schmidt, W. Kisiel, E. S. Connolly , Jr., and D. J. Pinsky Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage J. Exp. Med., July 5, 1999; 190(1): 91 - 100. [Abstract] [Full Text] [PDF]

				A. Roden-Jullig, M. Britton, and J. Svensson Antithrombin-III Activity and the Efficacy of Heparin in Progressing Ischemic Stroke Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 129 - 132. [Abstract] [PDF]

				T. F. Choudhri, B. L. Hoh, R. A. Solomon, E. S. Connolly Jr, and D. J. Pinsky Use of a Spectrophotometric Hemoglobin Assay to Objectively Quantify Intracerebral Hemorrhage in Mice Stroke, November 1, 1997; 28(11): 2296 - 2302. [Abstract] [Full Text]